Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board to consider FY19 results & Dividend on May 29, 2019

 Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on May 29, 2019, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2019 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2019.Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 01, 2019 to May 31, 2019 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2019.
14-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Board Meeting - 29Th May, 2019

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2019 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2019 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 1, 2019 to May 31, 2019 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2019.
14-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

 Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg
14-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Clarification sought from Glenmark Pharmaceuticals Ltd

 The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on https://economictimes.indiatimes.com May 13, 2019 titled "Pharma stocks bleed as US states file lawsuit against generic drug firms ". The reply is awaited.
13-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris(tm), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
09-05-2019
Bigul

Glenmark appoints Yasir Rawjee as CEO of Glenmark Life Sciences

 Glenmark's API business has witnessed robust growth rate of 15 per cent CAGR over the last five years
07-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its subsidiary for the API business
07-05-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO(r) Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
03-05-2019
Bigul

Glenmark expects up to 14 % growth in India revenues in FY20

 Drug major Glenmark Pharma expects 12 to 14 per cent growth in its India revenues during the current fiscal, a top company official said here on Thur
02-05-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGLENMARK PHARMACEUTICALS LTD. 2CININE935A01035 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: HARISH KUBER Designation: Company Secretary & Compliance Officer EmailId: complianceofficer@glenmarkpharma.com Name of the Chief Financial Officer: V S MANI Designation: Executive Director & Global Chief Financial Officer EmailId: VS.Mani@glenmarkpharma.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2019
Next Page
Close

Let's Open Free Demat Account